VOYAGER DIGITAL LT
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 162
- Market Cap
- $361.5M
- Introduction
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.
Safety and Tolerability Study With VY-HTT01, in Adults With Early Manifesting Huntington's Disease
Phase 1
Withdrawn
- Conditions
- Huntington Disease
- Interventions
- Genetic: Intraparenchymal rAAV1 - (mi)RNA HTT
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Voyager Therapeutics
- Registration Number
- NCT04885114
© Copyright 2025. All Rights Reserved by MedPath